Location History:
- Solingen, DE (2013)
- Cologne, DE (2020 - 2024)
Company Filing History:
Years Active: 2013-2024
Title: **Innovator Spotlight: Christian von Torne - A Pioneer in Breast Cancer Prognosis**
Introduction
Christian von Torne, based in Cologne, Germany, is a notable inventor whose work has significant implications in the field of oncology. With a focused approach towards improving breast cancer treatment outcomes, he has contributed valuable insights and methodologies that aid in patient prognosis.
Latest Patents
Christian von Torne holds a patent for a groundbreaking method titled "Method for Breast Cancer Recurrence Prediction Under Endocrine Treatment." This innovative method includes the detailed process of determining RNA expression levels of at least two out of nine specified genes from a tumor sample. The genes involved in his patent include UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP. By mathematically combining these expression level values, the method provides a combined score that is indicative of patient prognosis, highlighting its potential in improving clinical outcomes for individuals battling breast cancer.
Career Highlights
Christian’s career features a focus on harnessing genetic data to drive significant advancements in breast cancer treatment. His work at Myriad International GmbH points to a commitment to integrating research with practical applications in healthcare. Through his innovative efforts, he aims to bring new hope and precision to breast cancer management.
Collaborations
At Myriad International GmbH, Christian collaborates with esteemed colleagues, including Mareike Dartmann and Inke Sabine Feder. Together, they work to enhance the overall understanding of cancer treatment and contribute to the development of advanced prognostic tools that could transform patient care.
Conclusion
Christian von Torne's dedication to innovation in the field of cancer research exemplifies the critical role of inventors in advancing medical science. His patent not only showcases his expertise but also reflects the collaborative spirit of modern scientific inquiry. By focusing on predictive methodologies, he helps pave the way for improved patient outcomes in the fight against breast cancer.